FY2029 Earnings Estimate for Annexon Issued By HC Wainwright

Annexon, Inc. (NASDAQ:ANNX – Free Report) – Equities researchers at HC Wainwright increased their FY2029 earnings per share estimates for shares of Annexon in a report released on Tuesday, November 10th. HC Wainwright analyst A. Ghosh now expects that the company will earn $0.65 per share for the year, up from their previous forecast of $0.58. HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Annexon’s current full-year earnings is ($1.05) per share.

Annexon (NASDAQ:ANNX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03.

Several other research analysts also recently commented on the company. Wall Street Zen downgraded Annexon from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Citigroup began coverage on Annexon in a report on Tuesday, July 21st. They issued a “market underperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a research note on Thursday, October 15th. JPMorgan Chase & Co. upped their target price on shares of Annexon from $14.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, September 30th. Finally, Citizens Jmp raised shares of Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday, August 13th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $15.29.

Check Out Our Latest Report on Annexon

Annexon Stock Performance

Shares of NASDAQ:ANNX opened at $3.97 on Wednesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.79 and a quick ratio of 5.53. Annexon has a 1 year low of $2.54 and a 1 year high of $7.18. The firm has a market capitalization of $757.32 million, a PE ratio of -3.82 and a beta of 1.43. The business’s 50 day moving average price is $4.04 and its 200-day moving average price is $5.12.

Insiders Place Their Bets

In related news, CEO Douglas Love bought 26,065 shares of the stock in a transaction on Thursday, September 24th. The stock was bought at an average price of $3.83 per share, with a total value of $99,828.95. Following the completion of the purchase, the chief executive officer directly owned 390,476 shares in the company, valued at $1,495,523.08. This represents a 7.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 10.31% of the company’s stock.

Institutional Investors Weigh In On Annexon

Several large investors have recently added to or reduced their stakes in the business. Redmile Group LLC boosted its position in Annexon by 44.8% in the 1st quarter. Redmile Group LLC now owns 14,549,768 shares of the company’s stock valued at $80,606,000 after buying an additional 4,499,124 shares during the period. BlackRock Inc. purchased a new stake in shares of Annexon during the second quarter worth $77,312,000. Bank of America Corp DE increased its position in shares of Annexon by 165.3% during the first quarter. Bank of America Corp DE now owns 4,259,995 shares of the company’s stock worth $23,600,000 after acquiring an additional 2,654,414 shares during the period. Siren L.L.C. purchased a new stake in shares of Annexon during the first quarter worth $21,931,000. Finally, Palo Alto Investors LP acquired a new stake in shares of Annexon in the second quarter valued at $16,833,594.

Recent Annexon Headlines

Here are a few of the latest headlines about ANNX:

  • Positive Sentiment: HC Wainwright raised its FY2030 EPS forecast to $1.61 from $1.36 and its FY2029 estimate to $0.65 from $0.58, reflecting improved longer-range earnings expectations.
  • Neutral Sentiment: Despite the estimate revisions, HC Wainwright maintained its Buy rating and $14 target. A separate report said analysts’ consensus price target is $15.29. Article: Annexon consensus price target
  • Negative Sentiment: HC Wainwright cut EPS forecasts for Q4 2026 and each quarter of 2027, as well as FY2027 (to a loss of $0.99 per share from $0.69) and FY2028 (to a loss of $0.26 from $0.16). These revisions point to larger expected losses in the nearer term and could weigh on ANNX shares.

Annexon Company Profile

(Get Free Report)

Annexon is a clinical-stage biopharmaceutical company developing antibody-based therapies for diseases driven by the complement system, a part of the immune system involved in inflammation and tissue damage. The company focuses on the classical complement pathway, which it aims to inhibit selectively. Its investigational programs are designed for complement-related autoimmune, inflammatory and neurodegenerative conditions. These include treatments being studied for disorders affecting the nervous system and the eye.

See Also

Earnings History and Estimates for Annexon (NASDAQ:ANNX)

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.